Abstract Dipeptide peptidase IV（ DPP - 4） inhibitors as a novel oral hypoglycemic agents ， glucose-dependent mechanism of action based on incretin ， can reduce the overall three key indicators（ fasting blood glucose， postprandial blood glucose and glycosylated hemoglobin） ， while reducing the risk of hypoglycemia and weight gain ， with the protection of islet function ， may delay disease progression ， good safety and other therapeutic advantage .In this article the pharmacodynamic ， pharmacokinetic characteristics and security of DPP 4 inhibitors were reviewed.
